Literature DB >> 17063826

[CD8+ cytotoxic lymphocytes in cutaneous leishmaniasis].

Joselín Hernández-Ruiz1, Ingeborg Becker.   

Abstract

OBJECTIVE: Review of the literature on the role of CD8+ T cell in the immune response against Leishmania species that cause cutaneous leishmaniasis. The role of macrophages, dendritic cells, CD4 T cells and NK cells has been extensively analyzed in leishmaniasis, yet very little knowledge has been gained on CD8+ T cells in this disease. Murine models of leishmaniasis suggest that CD8+ T cells participate through IFNg production, yet their cytotoxic capacity may also play a crucial role, as has been found in human disease. It is an enigma what mechanisms underlie the CD8+ T cell activation. It is possible that dendritic cells activate CD8+ T cells through mechanisms that include antigen traspresentation. A better understanding of CD8+ T cells in the immune response against Leishmania will undoubtedly provide new insights into the physiopathogenesis of the disease that could lead to new therapeutic approaches against leishmaniasis.

Entities:  

Mesh:

Year:  2006        PMID: 17063826     DOI: 10.1590/s0036-36342006000500009

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  5 in total

1.  Parasite-derived arginase influences secondary anti-Leishmania immunity by regulating programmed cell death-1-mediated CD4+ T cell exhaustion.

Authors:  Zhirong Mou; Helen M Muleme; Dong Liu; Ping Jia; Ifeoma B Okwor; Shiby M Kuriakose; Stephen M Beverley; Jude E Uzonna
Journal:  J Immunol       Date:  2013-03-04       Impact factor: 5.422

2.  Protective and pathological functions of CD8+ T cells in Leishmania braziliensis infection.

Authors:  Thiago Marconi Cardoso; Álvaro Machado; Diego Luiz Costa; Lucas P Carvalho; Adriano Queiroz; Paulo Machado; Phillip Scott; Edgar M Carvalho; Olívia Bacellar
Journal:  Infect Immun       Date:  2014-12-22       Impact factor: 3.441

3.  Immunopathological characterization of human cutaneous leishmaniasis lesions caused by Leishmania (Viannia) spp. in Amazonian Brazil.

Authors:  Cláudia Maria Castro Gomes; Maria Gloria Teixeira Sousa; Joyce Prieto Bezerra Menezes; Marliane Campos Batista; Ana Carolina Stocco Lima; Walter Belda; Daniel Bradshaw; Monica Elinor Alves Gama; Márcia Dalastra Laurenti; Fernando Tobias Silveira; Carlos Eduardo Pereira Corbett
Journal:  Parasitol Res       Date:  2017-02-21       Impact factor: 2.289

4.  Development of an immunogen containing CD4+/CD8+ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis.

Authors:  Isabela de Andrade Ferraz; Ana Maria Ravena Severino Carvalho; Rory Cristiane Fortes de Brito; Bruno Mendes Roatt; Vívian Tamietti Martins; Daniela Pagliara Lage; Luiza Dos Reis Cruz; Fernanda Alvarenga Cardoso Medeiros; Denise Utsch Gonçalves; Manoel Otávio da Costa Rocha; Eduardo Antonio Ferraz Coelho; Tiago Antônio de Oliveira Mendes; Mariana Costa Duarte; Daniel Menezes-Souza
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-27       Impact factor: 5.560

5.  Efficacy of imiquimod 5% cream as first-line management in cutaneous leishmaniasis caused by Leishmania mexicana.

Authors:  Gabriela Fuentes-Nava; Andrés Tirado-Sánchez; Edith A Fernández-Figueroa; Sokani Sánchez-Montes; Ingeborg Becker; Alexandro Bonifaz
Journal:  Rev Soc Bras Med Trop       Date:  2021-03-22       Impact factor: 1.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.